Archives

  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • br In conclusion the incidence of total thyroidectomy has no

    2021-03-10


    In conclusion, the incidence of total thyroidectomy has not decreased despite evidence of equivalency with thyroid lobectomy and recommendations from the ATA encouraging thyroid lobec-tomy for PTC patients with smaller tumors. Further research is warranted to explore reasons for the lack of change in clinical surgical practice. As clinical behavior commonly lags behind new professional recommendations, ongoing population-based studies are also needed to monitor for future changes in practice.
    Conflicts of interest
    All authors have no actual or potential conflicts of interest to disclose.
    References
    1. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014;140:317e322. 2. Aschebrook-Kilfoy B, Kaplan EL, Chiu BC, Angelos P, Grogan RH. The accelera-tion in papillary thyroid cancer incidence rates is similar among racial and ethnic groups in the United States. Ann Surg Oncol. 2013;20:2746e2753.
    13. Lang BH, Wong CKH. Lobectomy is a more cost-effective option than total thyroidectomy for 1 to 4 cm papillary thyroid carcinoma that 3-Methyladenine do not possess clinically recognizable high-risk features. Ann Surg Oncol. 2016;23: 3641e3652.
    14. Aschebrook-Kilfoy B, Schechter RB, Shih YC, et al. The clinical and economic burden of a sustained increase in thyroid cancer incidence. Cancer Epidemiol Biomarkers Prev. 2013;22:1252e1259.
    15. Aschebrook-Kilfoy B, James B, Nagar S, et al. Risk factors for decreased quality of life in thyroid cancer survivors: Initial findings from the North American Thyroid Cancer Survivorship Study. Thyroid. 2015;25:1313e1321. 16. Applewhite MK, James BC, Kaplan SP, et al. 3-Methyladenine Quality of life in thyroid cancer is similar to that of other cancers with worse survival. World J Surg. 2016;40: 551e561.
    19. Mendelsohn AH, Elashoff DA, Abemayor E, St John MA. Surgery for papillary thyroid carcinoma: Is lobectomy enough? Arch Otolaryngol Head Neck Surg. 2010;136:1055e1061.
    23. Ebina A, Sugitani I, Fujimoto Y, Yamada K. Risk-adapted management of papillary thyroid carcinoma according to our own risk group classification system: Is thyroid lobectomy the treatment of choice for low-risk patients? Surgery. 2014;156:1579e1588; discussion 1588e1589.
    24. Kim MJ, Lee MC, Lee GH, et al. Extent of surgery did not affect recurrence during 7-years follow-up in papillary thyroid cancer sized 1-4 cm: Preliminary results. Clin Endocrinol (Oxf). 2017;87:80e86.
    25. Kuba S, Yamanouchi K, Hayashida N, et al. Total thyroidectomy versus thyroid lobectomy for papillary thyroid cancer: Comparative analysis after propensity score matching: A multicenter study. Int J Surg. 2017;38:143e148. 26. Barney BM, Hitchcock YJ, Sharma P, Shrieve DC, Tward JD. Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thy-roidectomy for differentiated thyroid cancer. Head Neck. 2011;33:645e649. 27. Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16:1229e1242. 28. Carhill AA, Litofsky DR, Ross DS, et al. Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS Registry Analysis 1987e2012. J Clin Endocrinol Metab. 2015;100:3270e3279. 29. Schvartz C, Bonnetain F, Dabakuyo S, et al. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J Clin Endocrinol Metab. 2012;97:1526e1535.
    30. Kim HJ, Kim NK, Choi JH, et al. Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma. Clin Endocrinol (Oxf). 2013;78:614e620.
    31. Hedman C, Strang P, Djarv€ T, Widberg I, Lundgren CI. Anxiety and fear of recurrence despite a Barr body good prognosis: An interview study with differentiated thyroid cancer patients. Thyroid. 2017;27:1417e1423.
    32. Aschebrook-Kilfoy B, Ferguson BA, Angelos P, et al. Development of the Thy-CAT: A clinically useful computerized adaptive test to assess quality of life in thyroid cancer survivors. Surgery. 2018;163:137e142.
    33. Sunavala-Dossabhoy G. Radioactive iodine: An unappreciated threat to salivary gland function. Oral Dis. 2018;24:198e201. 34. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16: 109e142.
    35. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thy-roid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167e1214.  36. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differen-tiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1e133.